The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines
Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Ne...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Nishida, Toshirou [verfasserIn] Blay, Jean-Yves [verfasserIn] Hirota, Seiichi [verfasserIn] Kitagawa, Yuko [verfasserIn] Kang, Yoon-Koo [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Gastric Cancer - Springer-Verlag, 2002, 19(2015), 1 vom: 15. Aug., Seite 3-14 |
|---|---|
| Übergeordnetes Werk: |
volume:19 ; year:2015 ; number:1 ; day:15 ; month:08 ; pages:3-14 |
| Links: |
|---|
| DOI / URN: |
10.1007/s10120-015-0526-8 |
|---|
| Katalog-ID: |
SPR009328386 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR009328386 | ||
| 003 | DE-627 | ||
| 005 | 20230519193101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201005s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10120-015-0526-8 |2 doi | |
| 035 | |a (DE-627)SPR009328386 | ||
| 035 | |a (SPR)s10120-015-0526-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nishida, Toshirou |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus. | ||
| 650 | 4 | |a Gastrointestinal stromal tumor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Guidelines |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Evidence-based |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Consensus based |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Blay, Jean-Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Hirota, Seiichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kitagawa, Yuko |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Yoon-Koo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gastric Cancer |d Springer-Verlag, 2002 |g 19(2015), 1 vom: 15. Aug., Seite 3-14 |w (DE-627)SPR009286586 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2015 |g number:1 |g day:15 |g month:08 |g pages:3-14 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s10120-015-0526-8 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2015 |e 1 |b 15 |c 08 |h 3-14 | ||
| author_variant |
t n tn j y b jyb s h sh y k yk y k k ykk |
|---|---|
| matchkey_str |
nishidatoshiroublayjeanyveshirotaseiichi:2015----:hsadrdanssramnadolwpfatonetnltoat |
| hierarchy_sort_str |
2015 |
| publishDate |
2015 |
| allfields |
10.1007/s10120-015-0526-8 doi (DE-627)SPR009328386 (SPR)s10120-015-0526-8-e DE-627 ger DE-627 rakwb eng Nishida, Toshirou verfasserin aut The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus. Gastrointestinal stromal tumor (dpeaa)DE-He213 Guidelines (dpeaa)DE-He213 Evidence-based (dpeaa)DE-He213 Consensus based (dpeaa)DE-He213 Blay, Jean-Yves verfasserin aut Hirota, Seiichi verfasserin aut Kitagawa, Yuko verfasserin aut Kang, Yoon-Koo verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 19(2015), 1 vom: 15. Aug., Seite 3-14 (DE-627)SPR009286586 nnns volume:19 year:2015 number:1 day:15 month:08 pages:3-14 https://dx.doi.org/10.1007/s10120-015-0526-8 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 19 2015 1 15 08 3-14 |
| spelling |
10.1007/s10120-015-0526-8 doi (DE-627)SPR009328386 (SPR)s10120-015-0526-8-e DE-627 ger DE-627 rakwb eng Nishida, Toshirou verfasserin aut The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus. Gastrointestinal stromal tumor (dpeaa)DE-He213 Guidelines (dpeaa)DE-He213 Evidence-based (dpeaa)DE-He213 Consensus based (dpeaa)DE-He213 Blay, Jean-Yves verfasserin aut Hirota, Seiichi verfasserin aut Kitagawa, Yuko verfasserin aut Kang, Yoon-Koo verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 19(2015), 1 vom: 15. Aug., Seite 3-14 (DE-627)SPR009286586 nnns volume:19 year:2015 number:1 day:15 month:08 pages:3-14 https://dx.doi.org/10.1007/s10120-015-0526-8 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 19 2015 1 15 08 3-14 |
| allfields_unstemmed |
10.1007/s10120-015-0526-8 doi (DE-627)SPR009328386 (SPR)s10120-015-0526-8-e DE-627 ger DE-627 rakwb eng Nishida, Toshirou verfasserin aut The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus. Gastrointestinal stromal tumor (dpeaa)DE-He213 Guidelines (dpeaa)DE-He213 Evidence-based (dpeaa)DE-He213 Consensus based (dpeaa)DE-He213 Blay, Jean-Yves verfasserin aut Hirota, Seiichi verfasserin aut Kitagawa, Yuko verfasserin aut Kang, Yoon-Koo verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 19(2015), 1 vom: 15. Aug., Seite 3-14 (DE-627)SPR009286586 nnns volume:19 year:2015 number:1 day:15 month:08 pages:3-14 https://dx.doi.org/10.1007/s10120-015-0526-8 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 19 2015 1 15 08 3-14 |
| allfieldsGer |
10.1007/s10120-015-0526-8 doi (DE-627)SPR009328386 (SPR)s10120-015-0526-8-e DE-627 ger DE-627 rakwb eng Nishida, Toshirou verfasserin aut The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus. Gastrointestinal stromal tumor (dpeaa)DE-He213 Guidelines (dpeaa)DE-He213 Evidence-based (dpeaa)DE-He213 Consensus based (dpeaa)DE-He213 Blay, Jean-Yves verfasserin aut Hirota, Seiichi verfasserin aut Kitagawa, Yuko verfasserin aut Kang, Yoon-Koo verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 19(2015), 1 vom: 15. Aug., Seite 3-14 (DE-627)SPR009286586 nnns volume:19 year:2015 number:1 day:15 month:08 pages:3-14 https://dx.doi.org/10.1007/s10120-015-0526-8 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 19 2015 1 15 08 3-14 |
| allfieldsSound |
10.1007/s10120-015-0526-8 doi (DE-627)SPR009328386 (SPR)s10120-015-0526-8-e DE-627 ger DE-627 rakwb eng Nishida, Toshirou verfasserin aut The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines 2015 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus. Gastrointestinal stromal tumor (dpeaa)DE-He213 Guidelines (dpeaa)DE-He213 Evidence-based (dpeaa)DE-He213 Consensus based (dpeaa)DE-He213 Blay, Jean-Yves verfasserin aut Hirota, Seiichi verfasserin aut Kitagawa, Yuko verfasserin aut Kang, Yoon-Koo verfasserin aut Enthalten in Gastric Cancer Springer-Verlag, 2002 19(2015), 1 vom: 15. Aug., Seite 3-14 (DE-627)SPR009286586 nnns volume:19 year:2015 number:1 day:15 month:08 pages:3-14 https://dx.doi.org/10.1007/s10120-015-0526-8 kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA AR 19 2015 1 15 08 3-14 |
| language |
English |
| source |
Enthalten in Gastric Cancer 19(2015), 1 vom: 15. Aug., Seite 3-14 volume:19 year:2015 number:1 day:15 month:08 pages:3-14 |
| sourceStr |
Enthalten in Gastric Cancer 19(2015), 1 vom: 15. Aug., Seite 3-14 volume:19 year:2015 number:1 day:15 month:08 pages:3-14 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Gastrointestinal stromal tumor Guidelines Evidence-based Consensus based |
| isfreeaccess_bool |
true |
| container_title |
Gastric Cancer |
| authorswithroles_txt_mv |
Nishida, Toshirou @@aut@@ Blay, Jean-Yves @@aut@@ Hirota, Seiichi @@aut@@ Kitagawa, Yuko @@aut@@ Kang, Yoon-Koo @@aut@@ |
| publishDateDaySort_date |
2015-08-15T00:00:00Z |
| hierarchy_top_id |
SPR009286586 |
| id |
SPR009328386 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009328386</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519193101.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-015-0526-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009328386</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-015-0526-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nishida, Toshirou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastrointestinal stromal tumor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Guidelines</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Evidence-based</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Consensus based</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blay, Jean-Yves</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hirota, Seiichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kitagawa, Yuko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kang, Yoon-Koo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">19(2015), 1 vom: 15. Aug., Seite 3-14</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">day:15</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:3-14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-015-0526-8</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="b">15</subfield><subfield code="c">08</subfield><subfield code="h">3-14</subfield></datafield></record></collection>
|
| author |
Nishida, Toshirou |
| spellingShingle |
Nishida, Toshirou misc Gastrointestinal stromal tumor misc Guidelines misc Evidence-based misc Consensus based The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines |
| authorStr |
Nishida, Toshirou |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)SPR009286586 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines Gastrointestinal stromal tumor (dpeaa)DE-He213 Guidelines (dpeaa)DE-He213 Evidence-based (dpeaa)DE-He213 Consensus based (dpeaa)DE-He213 |
| topic |
misc Gastrointestinal stromal tumor misc Guidelines misc Evidence-based misc Consensus based |
| topic_unstemmed |
misc Gastrointestinal stromal tumor misc Guidelines misc Evidence-based misc Consensus based |
| topic_browse |
misc Gastrointestinal stromal tumor misc Guidelines misc Evidence-based misc Consensus based |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Gastric Cancer |
| hierarchy_parent_id |
SPR009286586 |
| hierarchy_top_title |
Gastric Cancer |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)SPR009286586 |
| title |
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines |
| ctrlnum |
(DE-627)SPR009328386 (SPR)s10120-015-0526-8-e |
| title_full |
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines |
| author_sort |
Nishida, Toshirou |
| journal |
Gastric Cancer |
| journalStr |
Gastric Cancer |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
txt |
| container_start_page |
3 |
| author_browse |
Nishida, Toshirou Blay, Jean-Yves Hirota, Seiichi Kitagawa, Yuko Kang, Yoon-Koo |
| container_volume |
19 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Nishida, Toshirou |
| doi_str_mv |
10.1007/s10120-015-0526-8 |
| author2-role |
verfasserin |
| title_sort |
standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines |
| title_auth |
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines |
| abstract |
Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus. |
| abstractGer |
Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus. |
| abstract_unstemmed |
Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA |
| container_issue |
1 |
| title_short |
The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines |
| url |
https://dx.doi.org/10.1007/s10120-015-0526-8 |
| remote_bool |
true |
| author2 |
Blay, Jean-Yves Hirota, Seiichi Kitagawa, Yuko Kang, Yoon-Koo |
| author2Str |
Blay, Jean-Yves Hirota, Seiichi Kitagawa, Yuko Kang, Yoon-Koo |
| ppnlink |
SPR009286586 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1007/s10120-015-0526-8 |
| up_date |
2024-07-04T01:37:41.524Z |
| _version_ |
1803610553346686976 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR009328386</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230519193101.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201005s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s10120-015-0526-8</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR009328386</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s10120-015-0526-8-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Nishida, Toshirou</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Although gastrointestinal stromal tumors (GISTs) are a rare type of cancer, they are the commonest sarcoma in the gastrointestinal tract. Molecularly targeted therapy, such as imatinib therapy, has revolutionized the treatment of advanced GIST and facilitates scientific research on GIST. Nevertheless, surgery remains a mainstay of treatment to obtain a permanent cure for GIST even in the era of targeted therapy. Many GIST guidelines have been published to guide the diagnosis and treatment of the disease. We review current versions of GIST guidelines published by the National Comprehensive Cancer Network, by the European Society for Medical Oncology, and in Japan. All clinical practice guidelines for GIST include recommendations based on evidence as well as on expert consensus. Most of the content is very similar, as represented by the following examples: GIST is a heterogeneous disease that may have mutations in KIT, PDGFRA, HRAS, NRAS, BRAF, NF1, or the succinate dehydrogenase complex, and these subsets of tumors have several distinctive features. Although there are some minor differences among the guidelines—for example, in the dose of imatinib recommended for exon 9-mutated GIST or the efficacy of antigen retrieval via immunohistochemistry—their common objectives regarding diagnosis and treatment are not only to improve the diagnosis of GIST and the prognosis of patients but also to control medical costs. This review describes the current standard diagnosis, treatment, and follow-up of GISTs based on the recommendations of several guidelines and expert consensus.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Gastrointestinal stromal tumor</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Guidelines</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Evidence-based</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Consensus based</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Blay, Jean-Yves</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hirota, Seiichi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kitagawa, Yuko</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kang, Yoon-Koo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Gastric Cancer</subfield><subfield code="d">Springer-Verlag, 2002</subfield><subfield code="g">19(2015), 1 vom: 15. Aug., Seite 3-14</subfield><subfield code="w">(DE-627)SPR009286586</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:1</subfield><subfield code="g">day:15</subfield><subfield code="g">month:08</subfield><subfield code="g">pages:3-14</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s10120-015-0526-8</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2015</subfield><subfield code="e">1</subfield><subfield code="b">15</subfield><subfield code="c">08</subfield><subfield code="h">3-14</subfield></datafield></record></collection>
|
| score |
7.399599 |